Literature DB >> 9719365

Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF1 in children < or = 6 years and clinically suspected of having NF1. Neurofibromatosis team of Sophia Children's Hospital.

M H Cnossen1, K G Moons, M P Garssen, N M Pasmans, A de Goede-Bolder, M F Niermeijer, D E Grobbee.   

Abstract

OBJECTIVE: To establish the frequency of minor disease features in children with neurofibromatosis type 1 (NF1) and to evaluate the value of minor disease features in children < or = 6 years with a suspected diagnosis of NF1, considering that the disease is virtually 100% penetrant at 6 years of age.
DESIGN: During this 10 year, prospective, multidisciplinary, follow up study, 209 children suspected of having NF1 were examined; 150 were diagnosed with NF1 and 59 were not. The present analysis included children in whom NF1 was considered to be present at 6 years of age (n=85) and children without NF1 at 6 years of age (n=42).
RESULTS: The minor disease features macrocephaly (52.9%), short stature (24.7%), hypertelorism (63.5%), and thorax abnormalities (37.6%) were highly prevalent in children with NF1 and significantly associated with a diagnosis of NF1 at 6 years of age. In addition, the mean number of minor disease features was significantly higher in children with NF1 at 6 years of age compared to the group without a diagnosis at 6 years of age (mean 1.8 v 0.8, p<0.001). Moreover, children with three or more minor disease features were all diagnosed with NF1 under the age of 6 years. Multivariate analysis using a logistic regression model showed that macrocephaly, short stature, hypertelorism, and thorax abnormalities were all independently associated with the presence of NF1 at 6 years of age.
CONCLUSION: In children with insufficient diagnostic criteria aged < or = 6 years, documentation of minor disease features may be a helpful aid in predicting the diagnosis of NF1 in years to come.

Entities:  

Mesh:

Year:  1998        PMID: 9719365      PMCID: PMC1051384          DOI: 10.1136/jmg.35.8.624

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  14 in total

1.  Diagnostic delay in neurofibromatosis type 1.

Authors:  M H Cnossen; F J Smit; A de Goede-Bolder; P G Frets; H J Duivenvoorden; M F Niermeijer
Journal:  Eur J Pediatr       Date:  1997-06       Impact factor: 3.183

2.  A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity.

Authors:  S M Huson; D A Compston; P Clark; P S Harper
Journal:  J Med Genet       Date:  1989-11       Impact factor: 6.318

3.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations.

Authors:  R M Cawthon; R Weiss; G F Xu; D Viskochil; M Culver; J Stevens; M Robertson; D Dunn; R Gesteland; P O'Connell
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

4.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

Authors:  D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins
Journal:  Cell       Date:  1990-07-13       Impact factor: 41.582

5.  Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father.

Authors:  C Lázaro; A Ravella; A Gaona; V Volpini; X Estivill
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245

Review 6.  A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling.

Authors:  S M Huson; D A Compston; P S Harper
Journal:  J Med Genet       Date:  1989-11       Impact factor: 6.318

7.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes.

Authors:  D F Easton; M A Ponder; S M Huson; B A Ponder
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

8.  Diagnostic outcome in children with multiple café au lait spots.

Authors:  B R Korf
Journal:  Pediatrics       Date:  1992-12       Impact factor: 7.124

9.  The diagnosis of neurofibromatosis-1 in the child under the age of 6 years.

Authors:  A C Obringer; A T Meadows; E H Zackai
Journal:  Am J Dis Child       Date:  1989-06

10.  Penetrance of von Recklinghausen neurofibromatosis: a distinction between predecessors and descendants.

Authors:  V M Riccardi; R A Lewis
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

View more
  10 in total

1.  Disruption of Critical Period Plasticity in a Mouse Model of Neurofibromatosis Type 1.

Authors:  Mariska van Lier; M Hadi Saiepour; Koen Kole; Juliette E Cheyne; Nawal Zabouri; Thomas Blok; Yi Qin; Emma Ruimschotel; J Alexander Heimel; Christian Lohmann; Christiaan N Levelt
Journal:  J Neurosci       Date:  2020-06-11       Impact factor: 6.167

2.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

3.  Neurofibromatosis type 1 and infantile spasms.

Authors:  Martino Ruggieri; Paola Iannetti; Maurizio Clementi; Agata Polizzi; Gemma Incorpora; Alberto Spalice; Piero Pavone; Andrea Domenico Praticò; Maurizio Elia; Anna Lia Gabriele; Romano Tenconi; Lorenzo Pavone
Journal:  Childs Nerv Syst       Date:  2008-09-19       Impact factor: 1.475

4.  Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities.

Authors:  R G Steen; J S Taylor; J W Langston; J O Glass; V R Brewer; W E Reddick; R Mages; E K Pivnick
Journal:  AJNR Am J Neuroradiol       Date:  2001-05       Impact factor: 3.825

5.  An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation.

Authors:  M Upadhyaya; S M Huson; M Davies; N Thomas; N Chuzhanova; S Giovannini; D G Evans; E Howard; B Kerr; S Griffiths; C Consoli; L Side; D Adams; M Pierpont; R Hachen; A Barnicoat; H Li; P Wallace; J P Van Biervliet; D Stevenson; D Viskochil; D Baralle; E Haan; V Riccardi; P Turnpenny; C Lazaro; L Messiaen
Journal:  Am J Hum Genet       Date:  2006-12-08       Impact factor: 11.025

6.  Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.

Authors:  Marco Carotenuto; Maria Esposito
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

7.  Pediatric neurofibromatosis 1 and parental stress: a multicenter study.

Authors:  Maria Esposito; Rosa Marotta; Michele Roccella; Beatrice Gallai; Lucia Parisi; Serena Marianna Lavano; Marco Carotenuto
Journal:  Neuropsychiatr Dis Treat       Date:  2014-01-22       Impact factor: 2.570

8.  Bilateral and symmetrical anteromedial bowing of the lower limbs in a patient with neurofibromatosis type-I.

Authors:  Ali Al Kaissi; Klaus Klaushofer; Franz Grill; Rudolf Ganger
Journal:  Case Rep Orthop       Date:  2015-02-28

9.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

10.  Association between neurofibromatosis type 1 and cerebrovascular diseases in children: A systematic review.

Authors:  Beatriz Barreto-Duarte; Fabiana H Andrade-Gomes; María B Arriaga; Mariana Araújo-Pereira; Juan Manuel Cubillos-Angulo; Bruno B Andrade
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.